A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Alcon

Status and phase

Completed

Phase 3

Conditions

Ocular Hypertension

Glaucoma, Open-Angle

Treatments

Drug: Travoprost

Drug: Latanoprost

Study type

Interventional

Funder types

Industry

Identifiers

NCT00051142

C-01-36

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.